Serological surveillance of SARS-CoV-2 : Six-month trends and antibody response in a cohort of public health workers
Copyright © 2021. Published by Elsevier Ltd..
BACKGROUND: Antibody waning after SARS-CoV-2 infection may result in reduction in long-term immunity following natural infection and vaccination, and is therefore a major public health issue. We undertook prospective serosurveillance in a large cohort of healthy adults from the start of the epidemic in England.
METHODS: Clinical and non-clinical healthcare workers were recruited across three English regions and tested monthly from March to November 2020 for SARS-CoV-2 spike (S) protein and nucleoprotein (N) antibodies using five different immunoassays. In positive individuals, antibody responses and long-term trends were modelled using mixed effects regression.
FINDINGS: In total, 2246 individuals attended 12,247 visits and 264 were seropositive in ≥ 2 assays. Most seroconversions occurred between March and April 2020. The assays showed > 85% agreement for ever-positivity, although this changed markedly over time. Antibodies were detected earlier with Abbott (N) but declined rapidly thereafter. With the EuroImmun (S) and receptor-binding domain (RBD) assays, responses increased for 4 weeks then fell until week 12-16 before stabilising. For Roche (N), responses increased until 8 weeks, stabilised, then declined, but most remained above the positive threshold. For Roche (S), responses continued to climb over the full 24 weeks, with no sero-reversions. Predicted proportions sero-reverting after 52 weeks were 100% for Abbott, 59% (95% credible interval 50-68%) Euroimmun, 41% (30-52%) RBD, 10% (8-14%) Roche (N) < 2% Roche (S).
INTERPRETATION: Trends in SARS-CoV-2 antibodies following infection are highly dependent on the assay used. Ongoing serosurveillance using multiple assays is critical for monitoring the course and long-term progression of SARS-CoV-2 antibodies.
| Errataetall: |
CommentIn: J Infect. 2021 Aug;83(2):237-279. - PMID 33811939 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:82 |
|---|---|
| Enthalten in: |
The Journal of infection - 82(2021), 5 vom: 25. Mai, Seite 162-169 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Harris, Ross J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 30.04.2021 Date Revised 11.11.2023 published: Print-Electronic CommentIn: J Infect. 2021 Aug;83(2):237-279. - PMID 33811939 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jinf.2021.03.015 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM323224970 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM323224970 | ||
| 003 | DE-627 | ||
| 005 | 20231225183726.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jinf.2021.03.015 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1077.xml |
| 035 | |a (DE-627)NLM323224970 | ||
| 035 | |a (NLM)33766553 | ||
| 035 | |a (PII)S0163-4453(21)00132-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Harris, Ross J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Serological surveillance of SARS-CoV-2 |b Six-month trends and antibody response in a cohort of public health workers |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.04.2021 | ||
| 500 | |a Date Revised 11.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: J Infect. 2021 Aug;83(2):237-279. - PMID 33811939 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021. Published by Elsevier Ltd. | ||
| 520 | |a BACKGROUND: Antibody waning after SARS-CoV-2 infection may result in reduction in long-term immunity following natural infection and vaccination, and is therefore a major public health issue. We undertook prospective serosurveillance in a large cohort of healthy adults from the start of the epidemic in England | ||
| 520 | |a METHODS: Clinical and non-clinical healthcare workers were recruited across three English regions and tested monthly from March to November 2020 for SARS-CoV-2 spike (S) protein and nucleoprotein (N) antibodies using five different immunoassays. In positive individuals, antibody responses and long-term trends were modelled using mixed effects regression | ||
| 520 | |a FINDINGS: In total, 2246 individuals attended 12,247 visits and 264 were seropositive in ≥ 2 assays. Most seroconversions occurred between March and April 2020. The assays showed > 85% agreement for ever-positivity, although this changed markedly over time. Antibodies were detected earlier with Abbott (N) but declined rapidly thereafter. With the EuroImmun (S) and receptor-binding domain (RBD) assays, responses increased for 4 weeks then fell until week 12-16 before stabilising. For Roche (N), responses increased until 8 weeks, stabilised, then declined, but most remained above the positive threshold. For Roche (S), responses continued to climb over the full 24 weeks, with no sero-reversions. Predicted proportions sero-reverting after 52 weeks were 100% for Abbott, 59% (95% credible interval 50-68%) Euroimmun, 41% (30-52%) RBD, 10% (8-14%) Roche (N) < 2% Roche (S) | ||
| 520 | |a INTERPRETATION: Trends in SARS-CoV-2 antibodies following infection are highly dependent on the assay used. Ongoing serosurveillance using multiple assays is critical for monitoring the course and long-term progression of SARS-CoV-2 antibodies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Whitaker, Heather J |e verfasserin |4 aut | |
| 700 | 1 | |a Andrews, Nick J |e verfasserin |4 aut | |
| 700 | 1 | |a Aiano, Felicity |e verfasserin |4 aut | |
| 700 | 1 | |a Amin-Chowdhury, Zahin |e verfasserin |4 aut | |
| 700 | 1 | |a Flood, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Borrow, Ray |e verfasserin |4 aut | |
| 700 | 1 | |a Linley, Ezra |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmad, Shazaad |e verfasserin |4 aut | |
| 700 | 1 | |a Stapley, Lorraine |e verfasserin |4 aut | |
| 700 | 1 | |a Hallis, Bassam |e verfasserin |4 aut | |
| 700 | 1 | |a Amirthalingam, Gayatri |e verfasserin |4 aut | |
| 700 | 1 | |a Höschler, Katja |e verfasserin |4 aut | |
| 700 | 1 | |a Parker, Ben |e verfasserin |4 aut | |
| 700 | 1 | |a Horsley, Alex |e verfasserin |4 aut | |
| 700 | 1 | |a Brooks, Timothy J G |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Kevin E |e verfasserin |4 aut | |
| 700 | 1 | |a Ramsay, Mary E |e verfasserin |4 aut | |
| 700 | 1 | |a Ladhani, Shamez N |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infection |d 1982 |g 82(2021), 5 vom: 25. Mai, Seite 162-169 |w (DE-627)NLM012791822 |x 1532-2742 |7 nnns |
| 773 | 1 | 8 | |g volume:82 |g year:2021 |g number:5 |g day:25 |g month:05 |g pages:162-169 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jinf.2021.03.015 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 82 |j 2021 |e 5 |b 25 |c 05 |h 162-169 | ||